Tesofensine
Aliases: Tesofensine · NS2330
Last verified: 2026-09-23
The short version
A dopamine/norepinephrine/serotonin reuptake inhibitor — strong appetite suppression (Phase II: ~−10% weight); originally developed for Parkinson's/Alzheimer's. Status: in clinical trials. Investigational; not approved.
Identity & type
- Molecular type
- mali molekul
- Origin
- A dopamine/norepinephrine/serotonin reuptake inhibitor — strong appetite suppression (Phase II: ~−10% weight); originally developed for Parkinson's/Alzheimer's.
Mechanism of action
Monoamine reuptake inhibitor → central satiety and increased thermogenesis.
Dosing & routes
Official / clinical context
No approved official document exists for Tesofensine. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: 0.25–1 mg/day. Gray market: strong appetite loss and energy — users describe 3–6 kg/month, but with dry mouth, insomnia and elevated heart rate; caution with cardiovascular risks.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Gray market: strong appetite loss and energy — users describe 3–6 kg/month, but with dry mouth, insomnia and elevated heart rate; caution with cardiovascular risks.
Protocol — official vs community
Official / label
No approval (development for Alzheimer's/Parkinson's pivoted to obesity). Phase 2 obesity: 0.25–1 mg daily, ~10–12% weight loss at 0.5 mg.
- 01Start 0.25 mg daily
- 02Maintenance 0.5–1 mg daily
Duration: Trial-defined.
Triple monoamine reuptake inhibitor — the psychiatric-side-effect profile is why it isn't approved.
Community (anecdotal)
0.25–0.5 mg oral daily, sourced from gray markets where it appears (mostly EU-centric).
- Cycle:
- 8–12 weeks.
- Break:
- 4 weeks.
The insomnia/anxiety side-effect ceiling keeps community doses at the low end.
Human evidence
Successful Phase II in obesity; Phase III planned (Saniona).
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Dry mouth, insomnia, increased heart rate/pressure, nausea.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.